221 related articles for article (PubMed ID: 27222747)
1. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study.
Shah NV; Seth AK; Balaraman R; Aundhia CJ; Maheshwari RA; Parmar GR
J Adv Res; 2016 May; 7(3):423-34. PubMed ID: 27222747
[TBL] [Abstract][Full Text] [Related]
2. Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.
Murthy A; Ravi PR; Kathuria H; Malekar S
Nanomaterials (Basel); 2020 May; 10(6):. PubMed ID: 32486508
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization, and
Saghafi Z; Mohammadi M; Mahboobian MM; Derakhshandeh K
Drug Dev Ind Pharm; 2021 Mar; 47(3):509-520. PubMed ID: 33650445
[TBL] [Abstract][Full Text] [Related]
4. Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies.
Alhalmi A; Amin S; Khan Z; Beg S; Al Kamaly O; Saleh A; Kohli K
Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145519
[TBL] [Abstract][Full Text] [Related]
5. QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.
Pant A; Sharma G; Saini S; Kaur G; Jain A; Thakur A; Singh B
Drug Deliv Transl Res; 2024 Mar; 14(3):730-756. PubMed ID: 37768530
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
7. Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
Wei Q; Yang Q; Wang Q; Sun C; Zhu Y; Niu Y; Yu J; Xu X
AAPS PharmSciTech; 2018 Nov; 19(8):3661-3669. PubMed ID: 30324361
[TBL] [Abstract][Full Text] [Related]
8. Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.
Shah N; Seth A; Balaraman R; Sailor G; Javia A; Gohil D
Drug Dev Ind Pharm; 2018 Apr; 44(4):687-696. PubMed ID: 29168671
[TBL] [Abstract][Full Text] [Related]
9. Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout.
Ali Z; Din FU; Zahid F; Sohail S; Imran B; Khan S; Malik M; Zeb A; Khan GM
BMC Pharmacol Toxicol; 2022 Nov; 23(1):86. PubMed ID: 36443818
[TBL] [Abstract][Full Text] [Related]
10. Design and Optimization of Febuxostat-loaded Nano Lipid Carriers Using Full Factorial Design.
Bhatt S; Sharma JB; Kamboj R; Kumar M; Saini V; Mandge S
Turk J Pharm Sci; 2021 Feb; 18(1):61-67. PubMed ID: 33633486
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
12. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
13. Augmented Oral Bioavailability and Prokinetic Activity of Levosulpiride Delivered in Nanostructured Lipid Carriers.
Arif ST; Zaman SU; Khan MA; Tabish TA; Sohail MF; Arshad R; Kim JK; Zeb A
Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365165
[TBL] [Abstract][Full Text] [Related]
14. Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis.
Hosny KM; Bahmdan RH; Alhakamy NA; Alfaleh MA; Ahmed OA; Elkomy MH
J Pharm Sci; 2020 Jul; 109(7):2145-2155. PubMed ID: 32194094
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Pharmacokinetic Activity of Zotepine via Nanostructured Lipid Carrier System in Wistar Rats for Oral Application.
Tirumalesh C; Suram D; Dudhipala N; Banala N
Pharm Nanotechnol; 2020; 8(2):148-160. PubMed ID: 32096755
[TBL] [Abstract][Full Text] [Related]
16. Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 Jul; 12(7):1753-1773. PubMed ID: 34671949
[TBL] [Abstract][Full Text] [Related]
17. Development of Novel Solid Nanostructured Lipid Carriers for Bioavailability Enhancement Using a Quality by Design Approach.
Bajwa N; Mahal S; Naryal S; Singh PA; Baldi A
AAPS PharmSciTech; 2022 Sep; 23(7):253. PubMed ID: 36109467
[TBL] [Abstract][Full Text] [Related]
18. Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment.
Soni NK; Sonali LJ; Singh A; Mangla B; Neupane YR; Kohli K
Nanotechnology; 2020 Nov; 31(47):475101. PubMed ID: 32886644
[TBL] [Abstract][Full Text] [Related]
19. Nose to Brain Delivery of Astaxanthin-Loaded Nanostructured Lipid Carriers in Rat Model of Alzheimer's Disease: Preparation, in vitro and in vivo Evaluation.
Shehata MK; Ismail AA; Kamel MA
Int J Nanomedicine; 2023; 18():1631-1658. PubMed ID: 37020692
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured Lipid Carriers Loaded with Baicalin: An Efficient Carrier for Enhanced Antidiabetic Effects.
Shi F; Wei Z; Zhao Y; Xu X
Pharmacogn Mag; 2016; 12(47):198-202. PubMed ID: 27601850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
